miRNAs are well recognized as key regulators in the pathological events of IS, including atherosclerosis,17 hyperlipidemia,18 hypertension19 and plaque rupture.20 Inspired by the clinical application of oral SYK inhibitors as previously indicated,15 we further have been suggested that the decrease in SYK expression might be partially regulated by miRNA. The gene discussed is SYK; the disease is hyperlipidemia.